# A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components

> **NCT00819104** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 402 (actual)

## Conditions studied

- Primary Hypertension

## Interventions

- **DRUG:** Metoprolol XL 50mg + Amlodipine 5mg
- **DRUG:** Metoprolol XL 25 mg + Amlodipine 2.5mg
- **DRUG:** Metoprolol XL 50mg
- **DRUG:** Metoprolol XL 25 mg
- **DRUG:** Amlodipine 5mg

## Key facts

- **NCT ID:** NCT00819104
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** —
- **Final completion:** 2009-08
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2009-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00819104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00819104, "A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00819104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*